Becton Dickinson Reaches 50% Enrollment in Breast Surgery Trial
MT Newswires Live
Yesterday
Becton, Dickinson and Co. (BDX) said Thursday that its clinical study evaluating GalaFLEX LITE Scaffold in breast revision surgery for capsular contracture has treated 274 patients across 33 active US states.
The total number shows over 50% of planned enrollment and has triggered the first planned interim analysis, the medical technology company said.
The trial evaluates the bioabsorbable device for treating capsular contracture, a complication where scar tissue hardens around implants, the company said.
Shares of the company were down less than 1% in recent Thursday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.